Keryx Biopharmaceuticals (NASDAQ:KERX) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday, September 21st.
Other analysts have also recently issued reports about the company. Citigroup lowered their target price on Keryx Biopharmaceuticals from $4.75 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, August 9th. ValuEngine upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 21st. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Tuesday, July 10th. HC Wainwright started coverage on Keryx Biopharmaceuticals in a research report on Thursday, June 28th. They set a “buy” rating and a $9.00 price target on the stock. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $5.00 price target on shares of Keryx Biopharmaceuticals in a research report on Monday, June 25th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. Keryx Biopharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $6.25.
KERX traded up $0.03 on Friday, reaching $3.22. The company’s stock had a trading volume of 622,051 shares, compared to its average volume of 1,109,531. The company has a debt-to-equity ratio of -3.16, a quick ratio of 1.40 and a current ratio of 2.28. The company has a market capitalization of $409.56 million, a P/E ratio of -3.66 and a beta of 2.44. Keryx Biopharmaceuticals has a 1 year low of $2.78 and a 1 year high of $7.15.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. increased its stake in shares of Keryx Biopharmaceuticals by 3.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 536,951 shares of the biopharmaceutical company’s stock worth $2,197,000 after purchasing an additional 17,620 shares during the period. Swiss National Bank increased its stake in shares of Keryx Biopharmaceuticals by 13.0% in the first quarter. Swiss National Bank now owns 160,600 shares of the biopharmaceutical company’s stock worth $657,000 after purchasing an additional 18,500 shares during the period. Shufro Rose & Co. LLC increased its stake in shares of Keryx Biopharmaceuticals by 26.1% in the second quarter. Shufro Rose & Co. LLC now owns 91,800 shares of the biopharmaceutical company’s stock worth $345,000 after purchasing an additional 19,000 shares during the period. Boston Partners increased its stake in shares of Keryx Biopharmaceuticals by 14.2% in the second quarter. Boston Partners now owns 293,104 shares of the biopharmaceutical company’s stock worth $1,102,000 after purchasing an additional 36,544 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in shares of Keryx Biopharmaceuticals in the first quarter worth about $201,000. 59.52% of the stock is owned by institutional investors and hedge funds.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Featured Article: Penny Stocks
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.